Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.
The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.
Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.
The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.
Immunome, Inc. (Nasdaq: IMNM) reported its financial results for Q4 2022, revealing a net loss of $7.8 million, or $0.64 per share, against a total net loss of $36.9 million, or $3.09 per share, for the year. As of December 31, 2022, the company held $20.3 million in cash and equivalents. A noteworthy highlight includes a strategic collaboration with AbbVie, initiating the discovery of up to 10 novel antibody-target pairs, valued at up to $120 million per target. Additionally, preclinical data for its anti-EPN1 antibody showed promising results, indicating a significant tumor volume reduction when combined with existing treatments.
Immunome (Nasdaq: IMNM) announces that Chief Technology Officer Matthew Robinson, Ph.D., will present at the 13th Annual World ADC London conference from March 13-16, 2023. Dr. Robinson's talk on March 15 will focus on Immunome's Discovery Engine, a platform that uses human memory B cells to identify novel therapeutic targets for antibody-drug conjugates (ADCs). This proprietary technology aims to enhance cancer treatments by finding proteins selectively expressed on cancer cells. A copy of the presentation will be available post-event on Immunome's website.
Immunome, Inc. (NASDAQ: IMNM) has established an advisory board featuring Dr. John Lambert and Dr. Anthony Tolcher to enhance the prioritization of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities. These treatment modalities are becoming increasingly significant in oncology. Lambert emphasized the importance of identifying next-generation targets for successful ADC and TCR development, while Tolcher noted the growing clinical interest following recent FDA approvals. Immunome's proprietary Discovery Engine continues to uncover potential tumor-selective targets, aiming to broaden therapeutic options for cancer treatments.
Immunome has entered a multi-year collaboration with AbbVie to discover up to 10 novel target-antibody pairs through Immunome’s Discovery Engine. This agreement includes a $30M upfront payment and potential further payments totaling up to $70M for platform access, along with development milestones of up to $120M per target. AbbVie aims to enhance its oncology pipeline with Immunome’s innovative technology, which leverages human memory B cells for effective cancer therapeutics.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
What does Immunome, Inc. specialize in?
What is the core technology platform of Immunome?
What are the primary focus areas for Immunome?
Can you name some of Immunome's key pipeline assets?
Where is Immunome, Inc. based?
What is the goal of Immunome's development strategy?
How does Immunome identify high-affinity antibodies?
What distinguishes Immunome's approach to immunotherapy?
How does Immunome plan to impact cancer treatment?
What recent achievements has Immunome made?
